Also found in: Medical, Wikipedia.
EORTCEuropean Organization for Research and Treatment of Cancer
References in periodicals archive ?
SPECTA is a pan-European clinical trial site and cancer patient molecular screening network set up by EORTC in partnership with over 30 prime cancer treatment hubs in 11 European nations to supply efficient availability for patients to molecularly led clinical trials.
Michael Weller of the University Hospital Zurich, Chair of the EORTC Brain Tumor Group, and coordinator of this study commented "The EORTC is a leader in enabling multi-disciplinary approaches to investigate strategic therapeutic questions through clinical and translational research.
Although common sense favours preservation of kidney function especially with smaller tumours where a significant number are either benign or have less aggressive behaviour, the obsession in achieving ever-higher rates of PN with highly complex tumours in patients with normal renal function may have waned following the publication of the EORTC trial.
The EORTC promotes multidisciplinary cancer research in Europe and is linked to other leading biomedical research organizations around the world.
Founded in 1962, the EORTC is a nonprofit international cancer research organization under Belgian law.
Andrew Gengos, ImmunoCellular's Chief Executive Officer said, "Working with the EORTC is a key step in our strategy to establish a network of relationships within the clinical oncology community to support the conduct of the ICT-107 Phase 3 trial.
Results: The results obtained with EORTC QLQ-C30 showed significant improvements of several questionnaire-subscales.
The EORTC also assembled a laboratory research team that succeeded in identifying a molecular change in the tumour that predicts benefit from this new therapy.
Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase Ill trial, EORTC Head and Neck Cancer Cooperative Group.
To launch the roll-out the project, Alliance Boots held a joint press conference with the EORTC on 14 March in Brussels, in the presence of HRH Princess Astrid (Honorary President of the EORTC Charitable Trust).
7%), EORTC QLQ-C30 QOL scales (3/12 = 25%) and symptom scales (2/18 = 11.
Key recommendations from the new EORTC guidelines that will allow physicians to treat anaemia effectively in their cancer patients include: